KAPA: ENV105 targets CD105 to reverse cancer drug resistance, with pivotal trial data expected by 2027
CD105 was highlighted as a central driver of drug resistance in cancer, with ENV105 showing promise in reversing resistance and improving outcomes in prostate and lung cancer trials. Strategic collaborations, robust funding, and a multi-center academic consortium support ongoing and future clinical…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.